The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice

Psilocybin's persisting clinical effects are commonly attributed to activation of the serotonin 2A receptor, but its active metabolite binds to many serotonin receptor subtypes, including the serotonin 1B receptor (5-HT1BR). In mice, 5-HT1BR expression influenced brain-wide activity after psilocybin administration, measured by differences in c-Fos patterns across regions involved in emotional processing and cognitive function, including the amygdala and prefrontal cortex. 5-HT1BR mediated some acute and persisting behavioral effects: mice lacking 5-HT1BRs showed attenuated hypolocomotion to psilocybin, and both transgenic and pharmacological loss-of-function models indicated 5-HT1B involvement in decreased anhedonia and reduced anxiety-like behavior. The research implicates 5-HT1BR as a mediator of psilocybin's behavioral and neural effects in mice.

Study at a glance

Abstract

Abstract Recent studies highlight the promising use of psychedelic therapies for psychiatric disorders, including depression. The persisting clinical effects of psychedelics such as psilocybin are commonly attributed to activation of the serotonin 2A receptor (5-HT2AR) based on its role in the acute hallucinatory effects. However, the active metabolite of psilocybin binds to many serotonin receptor subtypes, including the serotonin 1B receptor (5-HT1BR). Given the known role of 5-HT1BR in mediating depressive phenotypes and promoting neural plasticity, we hypothesized that it mediates the effects of psilocybin on neural activity and behavior. We first examined the acute neural response to psilocybin in mice lacking 5-HT1BR. We found that 5-HT1BR expression influenced brain-wide activity following psilocybin administration, measured by differences in the patterns of the immediate early gene c-Fos, across regions involved in emotional processing and cognitive function, including the amygdala and prefrontal cortex. Functionally, we demonstrated that 5-HT1BR mediates some of the acute and persisting behavioral effects of psilocybin. Although there was no effect of 5-HT1BR expression on the acute head twitch response, mice lacking 5-HT1BRs had attenuated hypolocomotion to psilocybin. We also measured the persisting effects of psilocybin on anhedonia and anxiety-like behavior using transgenic and pharmacological 5-HT1BR loss-of-function models and found that 5-HT1B is involved in mediating the decreased anhedonia and reduced anxiety-like behavior. Finally, using a network analysis, we identified neural circuits through which 5-H1BR may modulate the response to psilocybin. Overall, our research implicates the 5-HT1BR, a non-hallucinogenic serotonin receptor, as a mediator of the behavioral and neural effects of psilocybin in mice.